Loading clinical trials...
Loading clinical trials...
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Conditions
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Antihemophilic factor, recombinant, manufactured protein-free
+1 more
Locations
8
United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Peoria, Illinois, United States
Iowa City, Iowa, United States
New Brunswick, New Jersey, United States
Cincinnati, Ohio, United States
Start Date
February 2, 2006
Primary Completion Date
April 1, 2007
Completion Date
April 1, 2007
Last Updated
June 10, 2021
NCT06820515
NCT07226206
NCT05987449
NCT04563520
NCT04645199
NCT06833983
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions